145 related articles for article (PubMed ID: 30996776)
41. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.
Desmond JC; Mountford JC; Drayson MT; Walker EA; Hewison M; Ride JP; Luong QT; Hayden RE; Vanin EF; Bunce CM
Cancer Res; 2003 Jan; 63(2):505-12. PubMed ID: 12543809
[TBL] [Abstract][Full Text] [Related]
42. Human dehydrogenase/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: Substrate and reaction specificity in the reduction of 11-keto-C
Endo S; Morikawa Y; Kudo Y; Suenami K; Matsunaga T; Ikari A; Hara A
J Steroid Biochem Mol Biol; 2020 May; 199():105586. PubMed ID: 31926269
[TBL] [Abstract][Full Text] [Related]
43. AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
Skarydová L; Zivná L; Xiong G; Maser E; Wsól V
Chem Biol Interact; 2009 Mar; 178(1-3):138-44. PubMed ID: 19007764
[TBL] [Abstract][Full Text] [Related]
44. Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines.
Verma K; Zang T; Gupta N; Penning TM; Trippier PC
ACS Med Chem Lett; 2016 Aug; 7(8):774-9. PubMed ID: 27563402
[TBL] [Abstract][Full Text] [Related]
45. Involvement of an aldo-keto reductase (AKR1C3) in redox cycling of 9,10-phenanthrenequinone leading to apoptosis in human endothelial cells.
Matsunaga T; Arakaki M; Kamiya T; Endo S; El-Kabbani O; Hara A
Chem Biol Interact; 2009 Sep; 181(1):52-60. PubMed ID: 19442656
[TBL] [Abstract][Full Text] [Related]
46. Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
Heinrich DM; Flanagan JU; Jamieson SM; Silva S; Rigoreau LJ; Trivier E; Raynham T; Turnbull AP; Denny WA
Eur J Med Chem; 2013 Apr; 62():738-44. PubMed ID: 23454516
[TBL] [Abstract][Full Text] [Related]
47. Characterization of a highly specific monoclonal antibody against human aldo-keto reductase AKR1C3.
Liu J; He P; Lin L; Zhao Y; Deng W; Ding H; Li Q; Wang Z
Steroids; 2019 Mar; 143():73-79. PubMed ID: 30639543
[TBL] [Abstract][Full Text] [Related]
48. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
49. Aldo-Keto Reductase 1C3 Mediates Chemotherapy Resistance in Esophageal Adenocarcinoma via ROS Detoxification.
Zhou C; Wang Z; Li J; Wu X; Fan N; Li D; Liu F; Plum PS; Hoppe S; Hillmer AM; Quaas A; Gebauer F; Chon SH; Bruns CJ; Zhao Y
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065695
[TBL] [Abstract][Full Text] [Related]
50. In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics.
Jamrozik M; Piska K; Bucki A; Koczurkiewicz-Adamczyk P; Sapa M; Władyka B; Pękala E; Kołaczkowski M
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175180
[TBL] [Abstract][Full Text] [Related]
51. Role of aldo-keto reductase enzymes in mediating the timing of parturition.
Byrns MC
Front Pharmacol; 2011; 2():92. PubMed ID: 22291648
[TBL] [Abstract][Full Text] [Related]
52. Analogues of Natural Chalcones as Efficient Inhibitors of AKR1C3.
Möller G; Temml V; Cala Peralta A; Gruet O; Richomme P; Séraphin D; Viault G; Kraus L; Huber-Cantonati P; Schopfhauser E; Pachmayr J; Tokarz J; Schuster D; Helesbeux JJ; Dyar KA
Metabolites; 2022 Jan; 12(2):. PubMed ID: 35208174
[TBL] [Abstract][Full Text] [Related]
53. Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
Wu CH; Ko JL; Chen SC; Lin YW; Han CP; Yang TY; Chien MH; Wang PH
Gynecol Oncol; 2014 Feb; 132(2):474-82. PubMed ID: 24316309
[TBL] [Abstract][Full Text] [Related]
54. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Doig CL; Battaglia S; Khanim FL; Bunce CM; Campbell MJ
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):47-55. PubMed ID: 26429394
[TBL] [Abstract][Full Text] [Related]
55. In situ proteolysis of an N-terminal His tag with thrombin improves the diffraction quality of human aldo-keto reductase 1C3 crystals.
Plavša JJ; Řezáčová P; Kugler M; Pachl P; Brynda J; Voburka Z; Ćelić A; Petri ET; Škerlová J
Acta Crystallogr F Struct Biol Commun; 2018 May; 74(Pt 5):300-306. PubMed ID: 29717998
[TBL] [Abstract][Full Text] [Related]
56. Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3.
Tavares TS; Hofman J; Lekešová A; Želazková J; Wsól V
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114555
[TBL] [Abstract][Full Text] [Related]
57. Screening, synthesis, crystal structure, and molecular basis of 6-amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles as novel AKR1C3 inhibitors.
Zheng X; Jiang Z; Li X; Zhang C; Li Z; Wu Y; Wang X; Zhang C; Luo HB; Xu J; Wu D
Bioorg Med Chem; 2018 Dec; 26(22):5934-5943. PubMed ID: 30429100
[TBL] [Abstract][Full Text] [Related]
58. In Vitro Evaluation of the Reductase Activities of Human
Takano S; Fukami T; Ichida H; Suzuki K; Nakano M; Nakajima M
Drug Metab Dispos; 2023 Sep; 51(9):1188-1195. PubMed ID: 37344179
[TBL] [Abstract][Full Text] [Related]
59. Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3).
Flanagan JU; Atwell GJ; Heinrich DM; Brooke DG; Silva S; Rigoreau LJ; Trivier E; Turnbull AP; Raynham T; Jamieson SM; Denny WA
Bioorg Med Chem; 2014 Feb; 22(3):967-77. PubMed ID: 24411201
[TBL] [Abstract][Full Text] [Related]
60. Roles of aldo-keto reductases 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Matsunaga T; Saito H; Endo S; Iguchi K; Soda M; El-Kabbani O; Hara A; Ikari A
Free Radic Res; 2016 Dec; 50(12):1296-1308. PubMed ID: 27629782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]